SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hamadani M)
 

Sökning: WFRF:(Hamadani M) > Reduced-Intensity A...

  • Klyuchnikov, EvgenyUniv Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany. (författare)

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors

  • Artikel/kapitelEngelska2015

Förlag, utgivningsår, omfång ...

  • Elsevier BV,2015
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-270421
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-270421URI
  • https://doi.org/10.1016/j.bbmt.2015.07.028DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:132455562URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • This study was conducted to compare long-term outcomes in patients with refractory/relapsed grades 1 and 2 follicular lymphoma (FL) after allogeneic (allo) versus autologous (auto) hematopoietic cell transplantation (HCT) in the rituximab era. Adult patients with relapsed/refractory grades 1 and 2 FL undergoing first reduced-intensity allo-HCT or first autograft during 2000 to 2012 were evaluated. A total of 518 rituximab-treated patients were included. Allo-HCT patients were younger and more heavily pretreated, and more patients had advanced stage and chemoresistant disease. The 5-year adjusted probabilities, comparing auto-HCT versus allo-HCT groups for nonrelapse mortality (NRM) were 5% versus 26% (P <.0001); relapse/progression: 54% versus 20% (P <.0001); progression-free survival (PFS): 41% versus 58% (P <.001), and overall survival (OS): 74% versus 66% (P =.05). Auto-HCT was associated with a higher risk of relapse/progression beyond 5 months after HCT (relative risk [RR], 4.4; P <.0001) and worse PFS (RR, 2.9; P <.0001) beyond 11 months after HCT. In the first 24 months after HO', auto-HCT was associated with improved OS (RR,.41; P <.0001), but beyond 24 months, it was associated with inferior OS (RR, 2.2; P =.006). A landmark analysis of patients alive and progression-free at 2 years after HO' confirmed these observations, showing no difference in further NRM between both groups, but there was significantly higher risk of relapse/progression (RR, 7.3; P <.0001) and inferior PFS (RR, 3.2; P <.0001) and OS (RR, 2.1; P =.04) after auto-HCT. The 10-year cumulative incidences of second hematological malignancies after allo-HCT and auto-HCT were 0% and 7%, respectively. Auto-HCT and reduced-intensity conditioned allo-HCT as first transplantation approach can provide durable disease control in grades 1 and 2 FL patients. Continued disease relapse risk after auto-HCT translates into improved PFS and OS after allo-HCT in long-term survivors.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Bacher, UlrikeUniv Gottingen, Dept Hematol & Internal Oncol, D-37073 Gottingen, Germany. (författare)
  • Kroeger, Nicolaus M.Univ Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany. (författare)
  • Hari, Parameswaran N.Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. (författare)
  • Ahn, Kwang WooMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. (författare)
  • Carreras, JeanetteMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. (författare)
  • Bachanova, VeronikaUniv Minnesota, Med Ctr, Bone & Marrow Transplant Program, Minneapolis, MN 55455 USA. (författare)
  • Bashey, AsadNorthside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA. (författare)
  • Cohen, Jonathon B.Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA. (författare)
  • D'Souza, AnitaMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. (författare)
  • Freytes, Cesar O.South Texas Vet Hlth Care Syst, San Antonio, TX USA.;Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.;Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England. (författare)
  • Gale, Robert Peter (författare)
  • Ganguly, SiddharthaUniv Kansas, Med Ctr, Blood & Marrow Transplantat, Div Hematol & Oncol, Kansas City, KS 66103 USA. (författare)
  • Hertzberg, Mark S.Prince Wales Hosp, Dept Haematol, Randwick, NSW 2031, Australia. (författare)
  • Holmberg, Leona A.Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. (författare)
  • Kharfan-Dabaja, Mohamed A.H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA. (författare)
  • Klein, AndreasTufts Med Ctr, Div Hematol Oncol, Dept Med, Boston, MA USA. (författare)
  • Ku, Grace H.Univ Calif San Diego, Dept Med, Div Blood & Marrow Transplantat, San Diego, CA 92103 USA. (författare)
  • Laport, Ginna G.Stanford Hosp & Clin, Div Bone Marrow Transplantat, Stanford, CA USA. (författare)
  • Lazarus, Hillard M.Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. (författare)
  • Miller, Alan M.Baylor Univ, Med Ctr, Dept Oncol, Dallas, TX USA. (författare)
  • Mussetti, AlbertoFdn IRCCS Ist Nazl Tumori, SC Ematol & Trapianto Midollo Osseo, Milan, Italy.;Univ Milan, Milan, Italy. (författare)
  • Olsson, Richard F.Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden.(Swepub:uu)riols677 (författare)
  • Slavin, ShimonInt Ctr Cell Therapy & Canc Immunotherapy, Tel Aviv, Israel. (författare)
  • Usmani, Saad Z.Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol, Med Oncol, Charlotte, NC USA. (författare)
  • Vij, RaviWashington Univ, Sch Med, Div Hematol & Oncol, St Louis, MO USA. (författare)
  • Wood, William A.Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA. (författare)
  • Maloney, David G.Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. (författare)
  • Sureda, Anna M.Hosp Duran & Reynals, Inst Catala Oncol, Serv Hematol, Barcelona, Spain.;European Grp Blood & Marrow Transplantat, Milan, Italy. (författare)
  • Smith, Sonali M.Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA. (författare)
  • Hamadani, MehdiMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. (författare)
  • Univ Canc Ctr Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany.Univ Gottingen, Dept Hematol & Internal Oncol, D-37073 Gottingen, Germany. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Biology of blood and marrow transplantation: Elsevier BV21:12, s. 2091-20991083-87911523-6536

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy